PMV Pharma Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
63
- Stock Symbol
-
PMVP
- Share Price
-
$1.50
- (As of Friday Closing)
PMV Pharma General Information
Description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Contact Information
Website
www.pmvpharma.comCorporate Office
- 8 Clarke Drive
- Suite 3
- Cranbury, NJ 08512
- United States
Corporate Office
- 8 Clarke Drive
- Suite 3
- Cranbury, NJ 08512
- United States
PMV Pharma Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.50 | $1.53 | $1.18 - $6.98 | $77.3M | 51.5M | 367K | -$0.97 |
PMV Pharma Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (101,579) | (30,630) | 150,961 | 751,847 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (75,505) | (78,872) | (76,638) | (57,965) |
| Net Income | (48,879) | (68,960) | (73,317) | (57,846) |
| Total Assets | 237,539 | 252,152 | 270,308 | 331,568 |
| Total Debt | 12,990 | 13,286 | 13,976 | 11,193 |
PMV Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PMV Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
PMV Pharma Comparisons
Industry
Financing
Details
000000
000000
PMV Pharma Competitors (61)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Outlook Therapeutic | Formerly VC-backed | Iselin, NJ | 00 | 00000 | 000000000 | 00000 |
| BeiGene | Formerly PE-Backed | Cambridge, MA | 0000 | 00.000 | 000000&0 | 00.000 |
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | 000 | 00000 | 000000&0 | 00000 |
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | 000 | 00.000 | 000000000 | 00.000 |
| Metacrine | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000&0 |
PMV Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PMV Pharma Patents
PMV Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240116910-A1 | Heterocycles as wip1 inhibitors | Pending | 14-Sep-2022 | 0000000000 | |
| US-20240100050-A1 | Mdm2 inhibitors and uses thereof | Pending | 12-Jul-2022 | 0000000000 | |
| US-20230301975-A1 | Deuterated compounds for restoring mutant p53 function | Active | 27-Jan-2022 | 0000000000 | |
| AU-2023213949-A1 | Deuterated compounds for restoring mutant p53 function | Pending | 27-Jan-2022 | 0000000000 | |
| US-11963953-B2 | Deuterated compounds for restoring mutant p53 function | Active | 27-Jan-2022 | A61K31/454 | 00 |
PMV Pharma Executive Team (12)
| Name | Title | Board Seat |
|---|---|---|
| David Mack Ph.D | Co-Founder, Board Member, President & Chief Executive Officer | |
| Michael Carulli | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Deepika Jalota | Executive | |
| Thomas Shenk Ph.D | Co-Founder & Member of the Scientific Advisory Board | |
| Robert Ticktin JD | General Counsel, Legal |
PMV Pharma Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Arnold Levine Ph.D | Self | Board Member | 000 0000 |
| Charles Baum Ph.D | Self | Board Member | 000 0000 |
| David Mack Ph.D | PMV Pharma | Co-Founder, Board Member, President & Chief Executive Officer | 000 0000 |
| Douglas Fisher MD | InterWest Health Partners | Board Observer | 000 0000 |
| Kirsten Flowers | Self | Board Member | 000 0000 |
PMV Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PMV Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PMV Pharma ESG
Risk Overview
Risk Rating
Updated May, 03, 2023
31.58 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
PMV Pharma FAQs
-
When was PMV Pharma founded?
PMV Pharma was founded in 2013.
-
Who is the founder of PMV Pharma?
David Mack Ph.D and Thomas Shenk Ph.D are the founders of PMV Pharma.
-
Who is the CEO of PMV Pharma?
David Mack Ph.D is the CEO of PMV Pharma.
-
Where is PMV Pharma headquartered?
PMV Pharma is headquartered in Cranbury, NJ.
-
What is the size of PMV Pharma?
PMV Pharma has 63 total employees.
-
What industry is PMV Pharma in?
PMV Pharma’s primary industry is Drug Discovery.
-
Is PMV Pharma a private or public company?
PMV Pharma is a Public company.
-
What is PMV Pharma’s stock symbol?
The ticker symbol for PMV Pharma is PMVP.
-
What is the current stock price of PMV Pharma?
As of 06-Sep-2024 the stock price of PMV Pharma is $1.50.
-
What is the current market cap of PMV Pharma?
The current market capitalization of PMV Pharma is $77.3M.
-
Who are PMV Pharma’s competitors?
Outlook Therapeutic, BeiGene, Dicerna Pharmaceuticals, Nektar Therapeutics, and Metacrine are some of the 61 competitors of PMV Pharma.
-
What is PMV Pharma’s annual earnings per share (EPS)?
PMV Pharma’s EPS for 12 months was -$0.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
